IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, ...
Medigene Files Patent for Unique NK-Specific TCR Construct with European Patent Office
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today ...
PipelineReview.com9h
Third Arc Bio Announces First Patient Dosed in Phase 1 Clinical Trial of Lead T Cell Engager ARC101 to Treat CLDN6 Positive Cancers
ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement ...
TipRanks on MSN4h
IN8bio reports Q4 EPS (8c), consensus (8c)
Reports as of December 31 the company had cash of $11.1M as of December 31, compared with $21.3M as of December 31, 2023. Subsequently, in ...
AHA/ASA Journals16h
Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction
BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...